KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Payables (2016 - 2025)

Abbott Laboratories' Payables history spans 17 years, with the latest figure at $5.3 billion for Q4 2025.

  • For Q4 2025, Payables rose 2.26% year-over-year to $5.3 billion; the TTM value through Dec 2025 reached $5.3 billion, up 2.26%, while the annual FY2025 figure was $5.3 billion, 2.26% up from the prior year.
  • Payables for Q4 2025 was $5.3 billion at Abbott Laboratories, up from $5.2 billion in the prior quarter.
  • Across five years, Payables topped out at $5.6 billion in Q1 2022 and bottomed at $4.8 billion in Q3 2023.
  • The 5-year median for Payables is $5.1 billion (2024), against an average of $5.2 billion.
  • The largest annual shift saw Payables rose 25.96% in 2021 before it fell 9.42% in 2023.
  • A 5-year view of Payables shows it stood at $5.2 billion in 2021, then grew by 4.87% to $5.5 billion in 2022, then dropped by 4.44% to $5.2 billion in 2023, then decreased by 0.59% to $5.2 billion in 2024, then rose by 2.26% to $5.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Payables are $5.3 billion (Q4 2025), $5.2 billion (Q3 2025), and $5.3 billion (Q2 2025).